Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia
Shallis RM, Bewersdorf JP, Boddu PC, Zeidan AM. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Review Of Anticancer Therapy 2019, 19: 717-729. PMID: 31422721, DOI: 10.1080/14737140.2019.1652095.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaHh pathway inhibitorsMyeloid leukemiaSurvival of AMLPathway inhibitorHh pathwayPoor-risk diseaseHedgehog pathway inhibitionStem cellsCombination therapyClinical trialsFirst approvalTherapeutic strategiesTherapeutic targetPathway inhibitionHematopoietic stem cellsNeoplasm therapyOlder populationTherapyHedgehog pathwayFurther studiesLeukemiaNormal hematopoiesisAdult stem cellsInhibitorsSMAC mimetics as potential cancer therapeutics in myeloid malignancies
Boddu P, Carter BZ, Verstovsek S, Pemmaraju N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. British Journal Of Haematology 2019, 185: 219-231. PMID: 30836448, DOI: 10.1111/bjh.15829.Peer-Reviewed Original ResearchMeSH KeywordsAntimetabolites, AntineoplasticApoptosisApoptosis Regulatory ProteinsHumansLeukemia, MyeloidMitochondrial ProteinsMolecular Targeted TherapyMyelodysplastic SyndromesPeptidomimeticsConceptsSmac mimeticsSmall-molecule Smac mimeticsSecond mitochondria-derived activatorEvasion of apoptosisPro-apoptotic proteinsPotential cancer therapeuticsMyeloid malignanciesIAP antagonismApoptosis proteinIAP expressionApoptosis thresholdDeath receptorsCaspase proteinsCell deathImmune check-point blockadeIAP activityReceptor tyrosine kinase inhibitorsCheck-point blockadeCancer therapeuticsEffect of chemotherapyDirect targetingProteinTumor necrosis factorFas ligandTyrosine kinase inhibitors